T

he U.S. National Institutes of Health plans to award an exclusive license for promising medical technology that was funded by U.S. taxpayers to a company controlled by a Chinese billionaire.

In a notice posted on the Federal Register on Monday, the agency proposed giving patent rights for antibody drugs that would be used to treat liver cancer to Salubris Biotherapeutics, a division of a company that is largely owned by Ye Chenghai, a former mayor of Shenzhen, China, who is the 51st richest person in China, according to Forbes.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The NIH gives its technology away to pharma companies all the time at taxpayer expense. Are we supposed to. E outraged just because the owner of this particular company is Chinese? This type of taxpayer subsidization is done and is rewarded with high drug prices. Why not write an article about this?

    • Hi Jim,

      Thanks for your note. To your point, I have written about taxpayer funded research leading to high pricing for a drug – in this instance, Xtandi.

      If you do a search on our site – using the terms ‘Xtandi,’ ‘price,’ and ‘patent,’ you’ll see several stories about the controversy.

      Let me know what you think,
      ed at pharmalot

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy